DataM Intelligence today announced its latest market intelligence release, “Genomics in Cancer Care Market: Size, Share, Industry, Forecast & Outlook (2024–2031),” revealing that genomics technologies are increasingly central to precision oncology, early detection, and personalized cancer therapies. As cancer incidence and demand for targeted treatments rise, the industry is seeing accelerating investment in diagnostic platforms, bioinformatics, and companion diagnostics. According to recent estimates, the market is expected to expand substantially by 2025, signalling strong momentum ahead.

 Download your Sample Report Instantly (Corporate Email ID required for priority access):

https://www.datamintelligence.com/download-sample/genomics-in-cancer-care-market?sv

Market Overview & Projections

• The Genomics in Cancer Care market was valued at approximately USD 13.4 billion in 2022.
  
  

• Under the projected growth trajectory, the market is forecast to reach USD 51.1 billion by 2031, reflecting a compound annual growth rate (CAGR) of about 18.9 % from 2024 to 2031.
  
  

• The report segments the market across technology (e.g., next-generation sequencing, PCR, microarrays, bioinformatics), application (diagnostics, prognostics, treatment selection, monitoring), sample type (blood, tissue, liquid biopsy), and region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa).
  
  

Market Segmentation Insights

• Technology: Next-generation sequencing (NGS) remains the backbone of genomics-based cancer care, enabling high-throughput mutation profiling, transcriptomics, and variant calling.
  
  

• Application: Diagnostic testing accounts for a large share, while treatment-selection and monitoring (including minimal residual disease, liquid biopsy) are growing rapidly in importance.
  
  

• Sample Type: Liquid biopsy and blood-based assays are gaining momentum for non-invasive cancer detection and monitoring.
  
  

• Region: North America currently leads in market share driven by strong infrastructure, research funding, and adoption in clinical practice. Asia-Pacific is forecast to be the fastest-growing region, supported by rising healthcare investment, expanding diagnostics infrastructure, and increasing cancer burden.
  
  

Regional Insights

• North America: Established genomics and biotech infrastructure, combined with favorable reimbursement policies, position the region as a market leader.
  
  

• Asia-Pacific: Countries like China, India, Japan, and South Korea are scaling up genomic R&D, building local sequencing & diagnostics capacity, and implementing cancer screening programs—poised to drive strong growth.
  
  

• Europe: Emphasis on regulatory harmonization, data privacy, and value-based care is accelerating adoption of genomics in cancer care.
  
  

Industry Trends & Recent Developments (2025)

• In 2025, the genomics in cancer care market is estimated to reach USD 20.56 billion, growing from USD 17.6 billion in 2024—implying a CAGR of ~16.8 %.
  
  

• Technology & Innovation:
    - Enhanced liquid biopsy assays (circulating tumor DNA, cell-free DNA) are being adopted for early detection, monitoring, and relapse prediction with growing clinical validation.
    - AI and machine learning integration in genomic analytics is improving variant calling accuracy, interpretation of complex genomic signatures, and predictive modeling in cancer care.
    - Novel multiplexed panels and targeted gene assays are being co-developed with oncology drug pipelines to drive companion diagnostics.
  
  

Strategic Moves:
  - Genomics & diagnostics firms are entering into partnerships with pharmaceutical companies and hospital networks to embed genomic testing in standard-of-care oncology workflows.